Responses
Clinical and epidemiological research
Extended report
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Compose a Response to This Article
Other responses
No responses have been published for this article.